Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Owens & Minor ( (OMI) ).
On May 8, 2025, Owens & Minor reported its first-quarter financial results, highlighting a mid-single-digit top-line growth in its Patient Direct segment, driven by strong performance in therapy categories like Diabetes and Sleep Supplies. The company also noted a 173 basis point expansion in the operating margin for this segment. Despite a net loss, the company reaffirmed its 2025 financial guidance, projecting revenue between $10.85 billion and $11.15 billion, and adjusted EBITDA between $560 million and $590 million. Owens & Minor remains engaged in the potential sale of its Products & Healthcare Services segment and is focused on disciplined capital deployment and integrating its planned acquisition of Rotech.
Spark’s Take on OMI Stock
According to Spark, TipRanks’ AI Analyst, OMI is a Neutral.
Owens & Minor’s overall stock score reflects significant financial challenges, including declining revenues and negative profitability margins. Technical indicators show bearish trends with some potential for rebound. Despite positive corporate events and a cautiously optimistic earnings call, the stock remains under pressure due to its financial instability and valuation concerns.
To see Spark’s full report on OMI stock, click here.
More about Owens & Minor
Owens & Minor, Inc. is a global healthcare solutions company that provides essential products and services supporting care from the hospital to the home. With over 100 years of experience, the company operates through its brands such as Apria, Byram, and HALYARD, serving patients, providers, and communities worldwide.
Average Trading Volume: 1,821,054
Technical Sentiment Signal: Sell
Current Market Cap: $595.6M
Learn more about OMI stock on TipRanks’ Stock Analysis page.